Home
KindredBio

KindredBio Market Share Analysis for February 2026

kindredbio is a leading veterinary biopharmaceutical company developing innovative medicines for cats, dogs, and horses. (nasdaq: kin)

Pets and Animals > Pet Food and Supplies

Domainkindredbio.com

Year Founded2012

Employees51 - 200

Annual Revenue$200M - $500M

KindredBio

KindredBio (including company regionals)

kindredbio.com

See more website traffic and engagement information

KindredBio Revenue up to February 2026 is 200M - 500M

revenue generated by KindredBio top domains

KindredBio top domains revenue over 3 years

Revenue for KindredBio top domains

kindredbio.com200M - 500M

See more with Sales Intelligence

Total visits to KindredBio's top domains

Understand KindredBio market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in KindredBio's top domains

Analyze KindredBio engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on KindredBio's top domains

See how KindredBio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

KindredBio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by KindredBio

These are the website technologies, by industry, used by KindredBio top domains

Advertising (13)

DoubleClick

Social (5)

Instagram

Conversion & Analytics (3)

Google Analytics

Widget (3)

Twemoji

More Technologies

13

See all

News & Signals from KindredBio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsElanco acquires KindredBio.For example, Elanco’s acquisitions of Kindred Biosciences and Aratana Therapeutics are recent instances of a large pharmaceutical player expanding its R&D capabilities through targeted acquisitions.

NewsKindredBio launched long-acting interleukin -31 antibody program on Apr 20th '21.On April 20, 2021, KindredBio unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the Company's novel half-life extension technology.

NewsKindredBio launched half-life extension technology for canine antibodies on Jan 1st '20.KindredBio first announced its half-life extension technology for canine antibodies in January 2020.